Brief: Cereno Signs CRO To Conduct Phase I Study Of Drug Candidate CS014
Sept 20 (Reuters) - Cereno Scientific AB CRNOSb.ST :
* CERENO SCIENTIFIC SIGNS CRO TO CONDUCT PHASE I STUDY OF
DRUG
CANDIDATE CS014
* FIRST-IN-HUMAN PHASE I STUDY IS PLANNED TO BE INITIATED
DURING
FIRST HALF OF 2024
Source text for Eikon: ID:nWkrbhFD8b
Further company coverage: CRNOSb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Cereno Scientific AB
See all newsBrief: Cereno Scientific Expects Up To 15 Activated Sites By 2026 In Epimode Trial
Brief: Cereno Scientific Reports Positive Results From Study
Brief: Cereno Scientific Q2 Net Sales Sek 0
Sweden's Cereno Scientific Q2 net loss widens, hurt by clinical development costs
Brief: Cereno Scientific Q2 Loss After Financial Items SEK 30.5 Mln